Table 4.
Clinical Outcome of study patients during in-hospital and 30-day follow-up based on MAGE levels
| MAGE (mmol/L) | <2.37 | 2.37-3.65 | >3.65 | P | |
|---|---|---|---|---|---|
| Subject number (n) |
237 |
80 |
78 |
79 |
NA |
| Composite MACE |
35 (14.8) |
6 (7.5) |
11 (14.1) |
18 (22.8) |
0.025 |
| Cardiac death |
4 (1.7) |
1 (1.3) |
1 (1.3) |
2 (2.5) |
0.775 |
| Reinfarction |
3 (1.3) |
0 (0) |
1 (1.3) |
2 (2.5) |
0.361 |
| Repeated TVR |
3 (1.3) |
0 (0) |
1 (1.3) |
2 (2.5) |
0.361 |
| Recurrent angina |
15 (6.3) |
3 (3.8) |
5 (6.4) |
7 (8.9) |
0.416 |
| Malignant arrhythmia |
10 (4.2) |
2 (2.5) |
3 (3.8) |
5 (6.3) |
0.477 |
| Non-cardiac death |
1 (0.4) |
0 (0) |
1 (1.3) |
0 (0) |
0.359 |
| Non-IRA revascularization | 53 (22.4) | 12 (15) | 16 (21) | 25 (32) | 0.037 |
Data given as mean ± SD or n (%).
MAGE, the mean amplitude of glycemic excursions; MACE, major adverse cardiac events; TVR, target vessel revascularization; IRA, infarct related arteries.